Episode Details

Precigens new drug, Pazopia, for adult recurrent respiratory papillomatosis, launched in November, generating $3.4 million in net product revenue in Q4. Full-year revenue surged 149% to $9.7 million. First-quarter 2026 revenue is projected to exceed $18 million. Patient numbers in their support hub have grown from 200 to over 300, with payer coverage expanding to 215 million lives. The drug, which received full FDA approval in August, is now considered the new standard of care by 16 top U.S. doctors. Despite a 22% drop in R&D costs, a 70% increase in selling and admin expenses led to a net loss. Precigen ended the year with $104 million in cash, aiming to reach breakeven by 2026. Upcoming plans include a permanent billing code starting April 1, a pediatric trial, European approval push, and progress on their cancer platform.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/81103d921b123c9b